Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹62,864 Cr
Revenue (TTM)
₹14,253 Cr
Net Profit (TTM)
₹2,371 Cr
ROE
19.9 %
ROCE
21.6 %
P/E Ratio
26.5
P/B Ratio
4.5
Industry P/E
27.85
EV/EBITDA
18.6
Div. Yield
0.9 %
Debt to Equity
0.1
Book Value
₹1170.9
EPS
₹201
Face value
2
Shares outstanding
119,565,000
CFO
₹10,747.07 Cr
EBITDA
₹15,811.68 Cr
Net Profit
₹12,550.63 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Alkem Laboratories
| -4.5 | -2.2 | -5.4 | 8.4 | 19.1 | 14.9 | 14.4 |
|
BSE Healthcare
| -2.6 | -1.7 | -3.7 | 3.2 | 25.2 | 15.5 | 10.7 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Alkem Laboratories
| -1.2 | 10.0 | 73.1 | -17.1 | 22.8 | 40.5 | 3.8 |
|
BSE Mid Cap
| 1.1 | 25.8 | 45.5 | 1.4 | 39.2 | 19.9 | -3.0 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Alkem Laboratories
|
5,257.5 | 62,864.3 | 14,252.7 | 2,424.5 | 17.5 | 19 | 26.5 | 4.5 |
| 26,715.0 | 56,804.1 | 6,824.1 | 1,524.1 | 25.9 | 37 | 37.3 | 12.9 | |
| 1,291.4 | 75,004.7 | 33,181.9 | 3,513.2 | 15.4 | 10.4 | 21.5 | 2.1 | |
| 381.0 | 61,740.4 | 16,827.4 | 629.6 | 9.6 | -0.1 | 102.2 | 1.6 | |
| 2,384.8 | 40,333.9 | 3,800.7 | 1,021.0 | 32.2 | 55 | 39.5 | 20.1 | |
| 1,544.9 | 39,246.8 | 9,504.5 | 947.8 | 15.9 | 14.6 | 43.1 | 5.0 | |
| 2,322.5 | 1,06,146.0 | 26,150.5 | 4,669.2 | 24.2 | 27 | 22.9 | 5.1 | |
| 2,000.0 | 82,555.3 | 13,914.1 | 1,792.3 | 17.8 | 12.6 | 46.4 | 5.3 | |
| 1,777.1 | 4,26,469.8 | 56,809.1 | 11,001.4 | 23.9 | 16.2 | 39.1 | 5.3 | |
| 890.5 | 89,615.2 | 26,089.3 | 4,933.9 | 24.7 | 21 | 18.1 | 3.4 |
How did MFs fare as anchor investors?
4 min read•By Kumar Shankar Roy
Alkem Laboratories Limited, a pharmaceutical company, engages in the development, manufacture, and sale of pharmaceutical and nutraceutical products in India and internationally. The company offers branded generics, generic drugs, active... pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, dermatology, cardiac, respiratory, gastro-intestinal, central nervous system, urology, and gynaecology, as well as vitamins, minerals, and nutrients; and pain analgesic, anti-diabetic, and neurology products. Alkem Laboratories Limited was incorporated in 1973 and is headquartered in Mumbai, India. Read more
Incorporated
1973
Chairman
Basudeo N Singh
Managing Director
Sandeep Singh
Headquarters
Mumbai, Maharashtra
Website
Looking for more details about Alkem Laboratories Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
The share price of Alkem Laboratories Ltd is ₹5,257.50 (NSE) and ₹5,257.75 (BSE) as of 20-Mar-2026 IST. Alkem Laboratories Ltd has given a return of 19.08% in the last 3 years.
The P/E ratio of Alkem Laboratories Ltd is 26.51 times as on 20-Mar-2026, a 5 discount to its peers’ median range of 27.85 times.
The P/B ratio of Alkem Laboratories Ltd is 4.49 times as on 20-Mar-2026, a 0 premium to its peers’ median range of 4.49 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
26.94
|
4.88
|
|
2024
|
32.89
|
5.74
|
|
2023
|
41.27
|
4.49
|
|
2022
|
26.28
|
5.01
|
|
2021
|
20.91
|
4.49
|
The 52-week high and low of Alkem Laboratories Ltd are Rs 5,933.50 and Rs 4,611.85 as of 23-Mar-2026.
Alkem Laboratories Ltd has a market capitalisation of ₹ 62,864 Cr as on 20-Mar-2026. As per SEBI classification, it is a Mid Cap company.
Before investing in Alkem Laboratories Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹17.50
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.